Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Novartis’ Pullicino to Helm EFPIA Japan from July
The European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan said on May 21 that Novartis Japan President John Paul Pullicino has been named its new chairman, effective July 1. His term will run through March 2027. Pullicino will succeed…
To read the full story
Related Article
- Boehringer’s Hasson Appointed EFPIA Japan Vice Chair
June 22, 2026
- Sanofi Japan Chief Iwaya to Step Down at June End, Leave EFPIA Role
April 16, 2026
- EFPIA Japan Appoints Novartis’ Pullicino as Vice Chair
January 9, 2026
- Pfizer Veteran Pullicino to Lead Novartis Japan
October 22, 2024
ORGANIZATION
- JETRO Opens 2026 Applications for Regenerative Medicine Program
July 2, 2026
- Incubator Led by Ex-Chugai CEO to Seek Govt Support, Raise Private Funds
June 30, 2026
- EFPIA Urges Global-Level Launch Prices, Patent-Term Price Protection
June 26, 2026
- Industry Hails Japan Growth Roadmap, PhRMA Urges Follow-Through
June 25, 2026
- Boehringer’s Hasson Appointed EFPIA Japan Vice Chair
June 22, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…